<DOC>
	<DOCNO>NCT00004380</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether parenteral relaxin improve skin tightness , Raynaud 's phenomenon , digital morbidity , digital ulcer patient progressive systemic sclerosis ( scleroderma ) . II . Determine whether relaxin decrease collagen production fibroblast vivo culture skin biopsy .</brief_summary>
	<brief_title>Phase II Study Recombinant Relaxin Progressive Systemic Sclerosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This compassionate use study . The patient treat subcutaneous injection recombinant relaxin approximately 12 month . If clinically indicate , therapy may extend .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Progressive systemic sclerosis ( scleroderma ) No pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>arthritis &amp; connective tissue disease</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic sclerosis</keyword>
</DOC>